Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 15;14(1):145.
doi: 10.1186/s13045-021-01159-2.

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

Xiao-Hui Zhang  1 , Jing Chen  2 , Ming-Zhe Han  3 , He Huang  4 , Er-Lie Jiang  3 , Ming Jiang  5 , Yong-Rong Lai  6 , Dai-Hong Liu  7 , Qi-Fa Liu  8 , Ting Liu  9 , Han-Yun Ren  10 , Yong-Ping Song  11 , Zi-Min Sun  12 , Xiao-Wen Tang  13 , Jian-Min Wang  14 , De-Pei Wu  13 , Lan-Ping Xu  1 , Xi Zhang  15 , Dao-Bin Zhou  16 , Xiao-Jun Huang  17   18
Affiliations

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

Xiao-Hui Zhang et al. J Hematol Oncol. .

Abstract

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.

Keywords: Allogeneic hematopoietic transplantation; China; Conditioning regimen; Consensus; Donor selection; Indication.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Algorithm for hematological malignancies
Fig. 2
Fig. 2
Algorithm for severe aplastic anemia
Fig. 3
Fig. 3
Algorithm for HIDs in hematological malignancies
See this image and copyright information in PMC

References

    1. Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, Zhang X, Song YP, Song XM, Hu JD, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant 2021;1-8. 10.1038/s41409-021-01431-6. - PMC - PubMed
    1. Niederwieser D. The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge. Bone Marrow Transplant. 2021;56:1229–1231. doi: 10.1038/s41409-021-01220-1. - DOI - PMC - PubMed
    1. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–1664. doi: 10.1038/s41409-021-01227-8. - DOI - PMC - PubMed
    1. Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020. https://www.cibmtr.org/.
    1. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177–e182. doi: 10.1016/j.bbmt.2020.04.013. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources